---
title: "湖北济川药业股份有限公司 (600566.SH)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/600566.SH.md"
symbol: "600566.SH"
name: "湖北济川药业股份有限公司"
industry: "制药"
---

# 湖北济川药业股份有限公司 (600566.SH)

| Item | Detail |
|------|--------|
| Industry | 制药 |
| Location | 沪深市场 |
| Website | [www.jumpcan.com](https://www.jumpcan.com) |

## Company Profile

公司是集中西医药、中药日化、中药保健三大产业为一体的国家级高新技术企业集团，国家火炬计划医药产业骨干企业，全国制药工业百强企业，上交所 A 股上市公司。公司主要从事药品的研发、生产和销售。公司主要产品为小儿豉翘清热颗粒 (商品名：同贝)、金同贝蒲地蓝消炎口服液、黄龙止咳颗粒、三拗片、健胃消食口服液、硫酸镁钠钾口服用浓溶液、甘海胃康胶囊。企业荣誉：高新技术企业;全省依法管理诚信经营先进单位;济川药业排名中国医药百强第 38 位;2017 中国医药上市公司竞争力 20 强奖杯;2017 中国医药上市公司十佳金牌董秘奖杯 “江苏省工人先锋号”“江苏省医药行业诚信企业”“全省医药行业统计工作先进单位”...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:10.000Z

**Overall: C (0.50)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 80 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -31.15% |  |
| Net Profit YoY | -40.64% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.81 |  |
| Dividend Ratio | 7.67% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 25.04B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 6.14B |  |


**Multi Score**: C

#### Profit Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 11.84% | B |
| Profit Margin | 26.88% | A |
| Gross Margin | 77.77% | A |

#### Growth Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -31.15% | E |
| Net Profit YoY | -40.64% | D |
| Total Assets YoY | -8.92% | E |
| Net Assets YoY | -1.68% | D |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 372.08% | C |
| OCF YoY | -31.15% | E |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.35 | C |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 16.18% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 湖北济川药业股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "A",
      "indicators": [
        {
          "name": "ROE",
          "value": "11.84%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "26.88%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "77.77%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "E",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-31.15%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-40.64%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-8.92%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-1.68%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "372.08%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-31.15%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.35",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "16.18%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 艾力斯 (SH.688578) | A | A | B | A | B | A |
| 02 | 兴齐眼药 (SZ.300573) | A | A | A | B | B | A |
| 03 | 恒瑞医药 (SH.600276) | A | B | C | A | B | B |
| 04 | 云南白药 (SZ.000538) | B | C | B | B | C | B |
| 05 | 信立泰 (SZ.002294) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 15.17 | 10/222 | 14.76 | 11.99 | 11.33 |
| PB | 1.81 | 61/222 | 1.81 | 1.75 | 1.66 |
| PS (TTM) | 4.08 | 98/222 | 3.97 | 3.51 | 3.33 |
| Dividend Yield | 7.67% | 3/222 | 8.06% | 7.71% | 4.82% |

## Institutional View

### Analyst Rating Distribution

> As of 2025-06-09T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 0 | 0% |
| Overweight | 1 | 100% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 27.18 |

## References

- [Company Overview](https://longbridge.com/en/quote/600566.SH/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/600566.SH/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/600566.SH/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
